References
  1. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alphα4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330(3):864–875.
  2. Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J 2014 Oct; 2(5): 333–344.
  3. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369(8):699–710.
  4. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, et al. GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369(8):711–721.
  5. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology 1994 Jul;107(1):103-8.
  6. Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, et al. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24(9):1876-1882.
  7. Perry C, Fischer K, Elmoursi A, Kern C, Currier A, Kudaravalli P, et al. Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis. Dig Dis Sci July 2020.
  8. Perin RL, Damião AOMC, Flores C, Ludvig JC, Magro OD, Miranda EF, et al. Vedolizumab in the management of inflammatory bowel diseases: a brazilian observational multicentric study. Arq Gastroenterol 2019;56(3):312-317.
  9. Zezos P, Kabakchiev B, Weizman AV, Nguyen GC, Narula N, Croitoru K, et al. Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. J Can Assoc Gastroenterol 2020;3(2):74-82.
  10. Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, et al. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019;17(8):1533-1540.e2.
  11. Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, et al. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. J Crohns Colitis 2019;13(9):1111-1120.
  12. Reenaers C, Cremer A, Dewit O, De Vroey B, Van Moerkercke W, Bossuyt P, et al. Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with Vedolizumab (Be-RELIVE). Acta Gastroenterol Belg 2020;83(1):15-23.
  13. Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, et al. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis 2018;24(4):849-860.
  14. Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, et al. Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort. Scand J Gastroenterol 2019;54(1):41-48.
  15. Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S. Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice–a nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016;43(10):1090-1102.
  16. Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Oldenburg B, de Boer NK, et al. Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab. Clin Pharmacol Ther 2020;107(5):1189-1199.
  17. Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, et al. Long-term clinical experience with vedolizumab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2011;17(suppl_1):S56-S56.
  18. Löwenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, et al. Vedolizumab induces endoscopic and histologic remission in patients with crohn’s disease. Gastroenterology 2019;157(4):997-1006.e6.
  19. Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: A multicenter cohort. Inflamm Bowel Dis 2015;21(12):2879-2885.
  20. Wendling D, Sondag M, Verhoeven F, Vuitton L, Koch S, Prati C. Arthritis occurrence or reactivation under Vedolizumab treatment for inflammatory bowel disease. A four cases report. Joint Bone Spine 2018;85(2):255-256.
  21. Dubash S, Marianayagam T, Tinazzi I, Al-Araimi T, Pagnoux C, Weizman AV, et al. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology (Oxford) 2019;58(6):963-968.
  22. Varkas G, Thevissen K, De Brabanter G, Van Praet L, Czul-Gurdian F, Cypers H, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis 2017;76:878–881.
  23. Dupré A, Collins M, Nocturne G, Carbonnel F, Mariette X, Seror R. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. Rheumatology (Oxford) 2020 Nov 1;59(11):3275-3283.
  24. Reinglas J, Gonczi L, Verdon C, Bessissow T, Afif W, Wild G, et al. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center. Dig Dis Sci 2020;65(7):2046-2053.
  25. Macaluso FS, Orlando R, Fries W, Scolaro M, Magnano A, Pluchino D, et al. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Dig Liver Dis 2018;50(7):675-681.
  26. Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, et al. Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci 2018;63(4):825-833.
  27. Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active crohn’s disease. Gastroenterology 2019;157(4):1007-1018.e7.
  28. Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther 2018;47(4):485-493.
  29. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews 2015;4(1):1.
  30. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
  31. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924.
  32. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352(24):2499-2507.
  33. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147(3):618-627.e3.
  34. Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, et al. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE 2019;14(2):e0212989.
  35. Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, et al. Vedolizumab as induction and maintenance therapy for crohn’s disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis 2017;23(1):97-106.
  36. Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, et al. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis 2019;13(1):50-57.
  37. Paccou J, Nachury M, Duchemin C, Desreumaux P, Flipo RM, Pariente B. Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease. Joint Bone Spine 2019 Oct;86(5):654-656.
  38. Mattheakis L, Bhandari A, Bai L, Zemede G, Tran V, Celino H, et al. PTG-100, An Oral Peptide Antagonist of Integrin α4β7 that Alters Trafficking of Gut Homing T Cells in Preclinical Animal Models. Inflammatory Bowel Diseases 2016; 22:S48.
  39. Lord JD, Long SA, Shows DM, Thorpe J, Schwedhelm K, Chen J, et al. Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. Clin Immunol 2018 Aug;193:24-32.
  40. Pollo A, Carlino E, Benedetti F. Placebo mechanisms across different conditions: from the clinical setting to physical performance. Philos Trans R Soc Lond B Biol Sci1 2011 Jun 27; 366(1572): 1790–1798.